This Tourette Syndrome Treatment market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The tourette syndrome treatment market size has grown strongly in recent years. It will grow from $2.37 billion in 2024 to $2.53 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to advancements in pharmacotherapy, clinical research and understanding, development of supportive therapies, improvements in diagnosis and awareness, and regulatory approvals and guidelines.
The tourette syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $3.24 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to advancements in precision medicine, expansion of telehealth services, integration of digital health solutions, increased research funding, and the rise of complementary and alternative therapies. Major trends in the forecast period include gene therapy advances, expanded access to care, non-pharmacological interventions, global collaborative initiatives, and the emergence of behavioral therapies.
The anticipated rise in healthcare spending is set to drive growth in the tourette syndrome treatment market. Healthcare spending encompasses all expenses on healthcare services and products, including treatments, medications, hospital stays, and preventive care, over a specific period, reflecting the overall healthcare costs within a population. This increase is fueled by the escalating costs of advanced medical technologies, aging populations, and the prevalence of chronic illnesses. In Tourette syndrome treatment, healthcare spending goes towards developing advanced diagnostic tools, medications, and behavioral therapies. It also supports ongoing research, patient education, and access to specialized care. For example, as reported by the National Institutes of Health in January 2024, healthcare spending in the US grew by 4.1% in 2022 to reach $4.5 trillion, marking a faster growth rate than the 3.2% increase seen in 2021. Consequently, the surge in healthcare spending is propelling the tourette syndrome treatment market forward.
Key players in the Tourette syndrome treatment market are concentrating on the development of advanced technologies, such as wearable devices designed to manage Tourette syndrome by entraining brain oscillations to suppress tics. These wearable devices provide electrical stimulation to the wrist, helping to reduce the frequency and intensity of tics. For example, in May 2022, Neurotherapeutics Ltd., a UK-based biotechnology firm, initiated a clinical trial for a wearable device tailored to Tourette syndrome. The device delivers targeted electrical stimulation to the median nerve at the wrist, aiming to influence brain oscillations associated with tic suppression. As a non-invasive and user-friendly treatment, it is designed to be easily incorporated into daily routines, allowing users to wear it at home comfortably. Its discreet, wristwatch-like design adds to its convenience and ease of use.
In April 2022, Saladax Biomedical Inc., a US-based company specializing in therapeutic drug monitoring (TDM) assays, acquired a patent portfolio related to antipsychotic drug testing from Janssen Pharmaceutica NV. for an undisclosed sum. This acquisition positions Saladax Biomedical to potentially enhance diagnostic tests and treatment approaches for Tourette syndrome by leveraging Janssen Pharmaceutica's antipsychotic drug intellectual property. Janssen Pharmaceutica NV., based in Belgium, is a key player in manufacturing, marketing, and distributing antipsychotic drugs utilized in treating tourette syndrome.
Major companies operating in the tourette syndrome treatment market are F Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Otsuka Pharmaceutical Co. Ltd., Biogen Inc., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Amneal Pharmaceuticals, Mallinckrodt Pharmaceuticals, Neurocrine Biosciences, Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals, Lundbeck AS, Voyager Therapeutics Inc., NeuroSigma Inc.
North America was the largest region in the tourette syndrome treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tourette syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tourette syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tourette syndrome treatment involves managing symptoms such as tics and behavioral issues through a variety of approaches, including medication, behavioral therapies, and supportive services. The goal is to decrease symptom frequency and severity while enhancing the overall quality of life for individuals with Tourette syndrome.
The main classes of drugs used in tourette syndrome treatment include antiadrenergic agents, antipsychotic agents, atypical antipsychotic agents, carbonic anhydrase inhibitors, anticonvulsants, and others. Antiadrenergic agents work by blocking or inhibiting the effects of adrenaline and noradrenaline. These medications are available through different channels such as hospital pharmacies, retail pharmacies, and online pharmacies, and are utilized in both pediatric and adult contexts.
The tourette syndrome treatment market research report is one of a series of new reports that provides tourette syndrome treatment market statistics, including tourette syndrome treatment industry global market size, regional shares, competitors with a tourette syndrome treatment market share, detailed tourette syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the tourette syndrome treatment industry. This tourette syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The tourette syndrome treatment market consists of revenues earned by entities by providing services, such as pharmacotherapy, behavioral therapies, neurostimulation techniques, and supportive services used during the process. The market value includes the value of related goods sold by the service provider or included within the service offering. The Tourette syndrome treatment market also includes sales of antipsychotics, wrist devices, and non-antipsychotic medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The tourette syndrome treatment market size has grown strongly in recent years. It will grow from $2.37 billion in 2024 to $2.53 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to advancements in pharmacotherapy, clinical research and understanding, development of supportive therapies, improvements in diagnosis and awareness, and regulatory approvals and guidelines.
The tourette syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $3.24 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to advancements in precision medicine, expansion of telehealth services, integration of digital health solutions, increased research funding, and the rise of complementary and alternative therapies. Major trends in the forecast period include gene therapy advances, expanded access to care, non-pharmacological interventions, global collaborative initiatives, and the emergence of behavioral therapies.
The anticipated rise in healthcare spending is set to drive growth in the tourette syndrome treatment market. Healthcare spending encompasses all expenses on healthcare services and products, including treatments, medications, hospital stays, and preventive care, over a specific period, reflecting the overall healthcare costs within a population. This increase is fueled by the escalating costs of advanced medical technologies, aging populations, and the prevalence of chronic illnesses. In Tourette syndrome treatment, healthcare spending goes towards developing advanced diagnostic tools, medications, and behavioral therapies. It also supports ongoing research, patient education, and access to specialized care. For example, as reported by the National Institutes of Health in January 2024, healthcare spending in the US grew by 4.1% in 2022 to reach $4.5 trillion, marking a faster growth rate than the 3.2% increase seen in 2021. Consequently, the surge in healthcare spending is propelling the tourette syndrome treatment market forward.
Key players in the Tourette syndrome treatment market are concentrating on the development of advanced technologies, such as wearable devices designed to manage Tourette syndrome by entraining brain oscillations to suppress tics. These wearable devices provide electrical stimulation to the wrist, helping to reduce the frequency and intensity of tics. For example, in May 2022, Neurotherapeutics Ltd., a UK-based biotechnology firm, initiated a clinical trial for a wearable device tailored to Tourette syndrome. The device delivers targeted electrical stimulation to the median nerve at the wrist, aiming to influence brain oscillations associated with tic suppression. As a non-invasive and user-friendly treatment, it is designed to be easily incorporated into daily routines, allowing users to wear it at home comfortably. Its discreet, wristwatch-like design adds to its convenience and ease of use.
In April 2022, Saladax Biomedical Inc., a US-based company specializing in therapeutic drug monitoring (TDM) assays, acquired a patent portfolio related to antipsychotic drug testing from Janssen Pharmaceutica NV. for an undisclosed sum. This acquisition positions Saladax Biomedical to potentially enhance diagnostic tests and treatment approaches for Tourette syndrome by leveraging Janssen Pharmaceutica's antipsychotic drug intellectual property. Janssen Pharmaceutica NV., based in Belgium, is a key player in manufacturing, marketing, and distributing antipsychotic drugs utilized in treating tourette syndrome.
Major companies operating in the tourette syndrome treatment market are F Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Otsuka Pharmaceutical Co. Ltd., Biogen Inc., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Amneal Pharmaceuticals, Mallinckrodt Pharmaceuticals, Neurocrine Biosciences, Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals, Lundbeck AS, Voyager Therapeutics Inc., NeuroSigma Inc.
North America was the largest region in the tourette syndrome treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tourette syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tourette syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tourette syndrome treatment involves managing symptoms such as tics and behavioral issues through a variety of approaches, including medication, behavioral therapies, and supportive services. The goal is to decrease symptom frequency and severity while enhancing the overall quality of life for individuals with Tourette syndrome.
The main classes of drugs used in tourette syndrome treatment include antiadrenergic agents, antipsychotic agents, atypical antipsychotic agents, carbonic anhydrase inhibitors, anticonvulsants, and others. Antiadrenergic agents work by blocking or inhibiting the effects of adrenaline and noradrenaline. These medications are available through different channels such as hospital pharmacies, retail pharmacies, and online pharmacies, and are utilized in both pediatric and adult contexts.
The tourette syndrome treatment market research report is one of a series of new reports that provides tourette syndrome treatment market statistics, including tourette syndrome treatment industry global market size, regional shares, competitors with a tourette syndrome treatment market share, detailed tourette syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the tourette syndrome treatment industry. This tourette syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The tourette syndrome treatment market consists of revenues earned by entities by providing services, such as pharmacotherapy, behavioral therapies, neurostimulation techniques, and supportive services used during the process. The market value includes the value of related goods sold by the service provider or included within the service offering. The Tourette syndrome treatment market also includes sales of antipsychotics, wrist devices, and non-antipsychotic medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Tourette Syndrome Treatment Market Characteristics3. Tourette Syndrome Treatment Market Trends and Strategies4. Tourette Syndrome Treatment Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Tourette Syndrome Treatment Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Tourette Syndrome Treatment Market34. Recent Developments in the Tourette Syndrome Treatment Market
5. Global Tourette Syndrome Treatment Growth Analysis and Strategic Analysis Framework
6. Tourette Syndrome Treatment Market Segmentation
7. Tourette Syndrome Treatment Market Regional and Country Analysis
8. Asia-Pacific Tourette Syndrome Treatment Market
9. China Tourette Syndrome Treatment Market
10. India Tourette Syndrome Treatment Market
11. Japan Tourette Syndrome Treatment Market
12. Australia Tourette Syndrome Treatment Market
13. Indonesia Tourette Syndrome Treatment Market
14. South Korea Tourette Syndrome Treatment Market
15. Western Europe Tourette Syndrome Treatment Market
16. UK Tourette Syndrome Treatment Market
17. Germany Tourette Syndrome Treatment Market
18. France Tourette Syndrome Treatment Market
19. Italy Tourette Syndrome Treatment Market
20. Spain Tourette Syndrome Treatment Market
21. Eastern Europe Tourette Syndrome Treatment Market
22. Russia Tourette Syndrome Treatment Market
23. North America Tourette Syndrome Treatment Market
24. USA Tourette Syndrome Treatment Market
25. Canada Tourette Syndrome Treatment Market
26. South America Tourette Syndrome Treatment Market
27. Brazil Tourette Syndrome Treatment Market
28. Middle East Tourette Syndrome Treatment Market
29. Africa Tourette Syndrome Treatment Market
30. Tourette Syndrome Treatment Market Competitive Landscape and Company Profiles
31. Tourette Syndrome Treatment Market Other Major and Innovative Companies
35. Tourette Syndrome Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Tourette Syndrome Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on tourette syndrome treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for tourette syndrome treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tourette syndrome treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug Class: Antiadrenergic Agents; Antipsychotic Agents; Atypical Antipsychotic Agents; Carbonic Anhydrase Inhibitor Anticonvulsants; Other Drug Classes2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By Application: Children; Adult
Subsegments:
1) By Antiadrenergic Agents: Alpha-2 Adrenergic Agonists; Beta-Blockers2) By Antipsychotic Agents: Typical Antipsychotics; Atypical Antipsychotics
3) By Atypical Antipsychotic Agents: Risperidone; Aripiprazole
4) By Carbonic Anhydrase Inhibitor Anticonvulsants: Topiramate; Zonisamide
5) By Other Drug Classes: Dopamine-Depleting Agents; Gabaergic Drugs
Key Companies Mentioned: F Hoffmann-La Roche AG; AbbVie Inc.; Bayer AG; Sanofi S.a.; Bristol-Myers Squibb
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Tourette Syndrome Treatment market report include:- F Hoffmann-La Roche AG
- AbbVie Inc.
- Bayer AG
- Sanofi S.A.
- Bristol-Myers Squibb
- AstraZeneca PLC
- Novartis International AG
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Viatris Inc.
- Otsuka Pharmaceutical Co. Ltd.
- Biogen Inc.
- Eisai Co. Ltd.
- Jazz Pharmaceuticals plc
- Mitsubishi Tanabe Pharma Corporation
- Kyowa Kirin Co. Ltd.
- Amneal Pharmaceuticals
- Mallinckrodt Pharmaceuticals
- Neurocrine Biosciences
- Sunovion Pharmaceuticals Inc.
- Supernus Pharmaceuticals
- Lundbeck AS
- Voyager Therapeutics Inc.
- NeuroSigma Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | April 2025 |
Forecast Period | 2025 - 2029 |
Estimated Market Value ( USD | $ 2.53 Billion |
Forecasted Market Value ( USD | $ 3.24 Billion |
Compound Annual Growth Rate | 6.4% |
Regions Covered | Global |
No. of Companies Mentioned | 25 |